The Sec61 translocon is a therapeutic vulnerability in multiple myeloma

Multiple myeloma (MM) is an incurable malignancy characterized by the uncontrolled expansion of plasma cells in the bone marrow. While proteasome inhibitors like bortezomib efficiently halt MM progression, drug resistance inevitably develop, and novel therapeutic approaches are needed. Here, we used...

Descripción completa

Detalles Bibliográficos
Autores principales: Domenger, Antoine, Choisy, Caroline, Baron, Ludivine, Mayau, Véronique, Perthame, Emeline, Deriano, Ludovic, Arnulf, Bertrand, Bories, Jean‐Christophe, Dadaglio, Gilles, Demangel, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899908/
https://www.ncbi.nlm.nih.gov/pubmed/35014767
http://dx.doi.org/10.15252/emmm.202114740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899908/
https://www.ncbi.nlm.nih.gov/pubmed/35014767
http://dx.doi.org/10.15252/emmm.202114740

Ejemplares similares